HURAHealthcare · BiotechnologyThe 4 Wall Street analysts covering TuHURA Biosciences, Inc. hold a median 12-month price target of $8 — +288.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 29 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores TuHURA Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (71): Smaller than most of the companies we track.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +288.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 18 Aug 2026 | Citizens | Reiterates | Market Outperform | $9.00 |
| 27 Apr 2026 | Citizens | Initiates | Market Outperform | — |
| 27 Apr 2026 | Citizens | Initiates | Market Outperform | $9.00 |
| 3 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2025 | Maxim Group | Maintains | Buy | — |
| 16 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 19 Dec 2024 | Rodman & Renshaw | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HURA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, TuHURA Biosciences, Inc. returned −15.9% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 12% of US stocks
Cheaper than 80% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TuHURA Biosciences, Inc. has a market value of $134.5M and an enterprise value of $142.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$30.6M.
Free cash flow in the twelve months to 30 June 2026: −$29.9M.
TuHURA Biosciences, Inc. spent $8K on dividends in the twelve months to 30 June 2026.
Trailing P/E: −3.4×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
TuHURA Biosciences, Inc. employs 22 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TuHURA Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
TuHURA reported confirmed partial responses in the first three evaluable frontline patients in its ongoing open-label Phase 1b study of IFx-2.0 for metastatic Merkel cell carcinoma.
Why it matters — The preliminary responses provide early clinical data on TuHURA’s IFx-2.0 program in metastatic Merkel cell carcinoma.
TuHURA Biosciences announced preliminary data from the first three patients in its open-label study of IFx-2.0 alongside Keytruda as first-line treatment for metastatic Merkel cell carcinoma. The company said the results showed major objective tumor responses at six months.
Why it matters — The early study update gives HURA watchers preliminary information on the clinical results for IFx-2.0 in combination with Keytruda.
TuHURA Biosciences announced that the USPTO issued a new U.S. patent for its VISTA inhibitor, TBS-2025. The patent broadens coverage to include bispecific and multi-specific antibodies across all classes of human antibodies.
Why it matters — The expanded patent coverage may be relevant to HURA watchers assessing the company’s intellectual-property position around TBS-2025.
TuHURA Biosciences announced that the U.S. Patent and Trademark Office has issued a key U.S. patent covering its Delta Opioid Receptor (DOR) antibody drug conjugate (ADC) technology. The patent also discloses additional uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies such as CAR-T, Tregs, or TIL cell therapies.
Why it matters — This patent strengthens TuHURA's intellectual property protection for its DOR ADC technology and its potential expansion into cell-based immunotherapies, which could broaden the company's therapeutic scope beyond its current Phase 3 pipeline.
TuHURA Biosciences announced that the FDA has issued a "Study May Proceed" notice and cleared the company's Investigational New Drug application for TBS-2025, a VISTA-inhibiting antibody being evaluated for molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.
Why it matters — This regulatory clearance allows TuHURA to expand its pipeline beyond its Phase 3 immuno-oncology work into a new area, advancing development of a novel VISTA-inhibiting antibody for blood cancers.
The 4 Wall Street analysts covering TuHURA Biosciences, Inc. have a median 12-month price target of $8, with estimates ranging from $6.2 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering TuHURA Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TuHURA Biosciences, Inc. 16 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, TuHURA Biosciences, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +288.3% from the last close, and Ticker Nerd's factor model ranks TuHURA Biosciences, Inc. 16 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TuHURA Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.2 to $10 over the next 12 months.
TuHURA Biosciences, Inc. returned -15.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy.
The most recent item we track (MarketBeat, 26 Oct 2026): "TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study". TuHURA reported confirmed partial responses in the first three evaluable frontline patients in its ongoing open-label Phase 1b study of IFx-2.0 for metastatic Merkel cell carcinoma.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, including IFx-2.0, an innate immune agonist intended to enhance responses to checkpoint inhibitors, and additional technologies aimed at addressing both primary and acquired resistance in the tumor microenvironment. TuHURA Biosciences also works on personalized cancer vaccines and bi-functional antibody-drug conjugates that target immune-suppressing cells linked to treatment resistance. Based in Tampa, Florida, TuHURA Biosciences operates in the biotechnology and oncology drug development sectors, where its programs are intended to support combination approaches for difficult-to-treat cancers and advance late-stage clinical research in immunotherapy.
CEO Dr. James A. Bianco M.D. · 22 employees · United States · https://www.tuhurabio.com
